10 completed, 1 active not recruiting, 1 not yet recruiting. 12 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 10, Active not recruiting 1, Not yet recruiting 1 |
| Phase 3 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Dust Mite Allergy: new trials by email Literature Review of Dust Mite Allergy trials Research Report on Dust Mite Allergy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract 3,000 MM09, 9,000 MM09, Placebo sublingual - Allergic Rhinitis, Allergic Asthma | Phase 2 / Phase 3 | Not yet recruiting | Inmunotek S.L. | 90 | 2023-11-01 | 2023-10-23 |
| Dupilumab Effects Against Aeroallergen Challenge Dupilumab, House Dust Mites (HDM), Placebo - Asthma, Allergic | Phase 2 | Active not recruiting | The University of Texas Health Science Center at San Antonio | 96 | 2023-03-29 | 2026-08-11 |
| Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients Tregalizumab, Placebo - Allergy to House Dust Mite, Allergic Asthma | Phase 2 | Completed | T-Balance Therapeutics GmbH | 42 | 2020-12-09 | 2022-02-08 |
| Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients Placebo solution, hdmASIT+TM - House Dust Mite Allergy | Phase 2 | Completed | ASIT Biotech S.A. | 36 | 2016-09-28 | 2017-03-29 |
| SUBLIVAC FIX Mite Mixture Dose Tolerability Study SUBLIVAC FIX Mite mixture, Placebo - House Dust Mite Allergy | Phase 1 / Phase 2 | Completed | HAL Allergy | 81 | 2015-05-01 | 2015-12-02 |
| Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma SLIT tablets of HDM allergen extracts, 3 different doses (A), SLIT tablets of HDM allergen extracts, 3 different doses (B), SLIT tablets of HDM allergen extracts, 3 different doses (C) - Asthma, House Dust Mite Allergy | Phase 2 | Completed | Stallergenes Greer | 386 | 2013-09-01 | 2015-12-18 |
| Biological Standardization of Dermatophagoides Pteronyssinus Allergen Extract Prick test Dermatophagoides pteronyssinus allergen extract - Allergy Dermatophagoides Pteronyssinus, Allergic Rhinitis | Phase 2 | Completed | Laboratorios Leti, S.L. | 42 | 2013-03-01 | 2018-02-23 |
| Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus in Local Allergic Rhinitis Pangramin Plus D. pteronyssinus, Placebo - Local Allergic Rhinitis | Phase 2 | Completed | Miguel Blanca Gomez | 36 | 2010-01-01 | 2016-03-31 |
| Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With Rhinoconjunctivitis Toleromune HDM, Placebo - Allergy | Phase 2 | Completed | Circassia Limited | 50 | 2009-11-01 | 2010-11-10 |
| A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10), House dust mite allergen extract in combination with CYT003-QbG10-placebo - Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy | Phase 2 | Completed | Cytos Biotechnology AG | 100 | 2007-11-01 | 2009-04-27 |
| A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10), House dust mite allergen extract in combination with CYT003-QbG10-placebo, CYT003-AllQbG10 in combination with house dust mite allergen extract placebo - Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy | Phase 2 | Completed | Cytos Biotechnology AG | 40 | 2006-09-01 | 2013-07-11 |
| Fish Oil and Asthma in House Dust Mite Allergy polyunsatturated fatty acids (fish oil) - Allergic Asthma, Bronchial Inflammation | Phase 2 / Phase 3 | Completed | Johann Wolfgang Goethe University Hospital | 23 | 2004-04-01 | 2006-09-29 |
Hypersensitivity (3) · Rhinitis, Allergic (3) · Asthma (2) · Rhinitis (1)
Hypersensitivity, Immediate (12) · Immune System Diseases (12) · Nose Diseases (12) · Otorhinolaryngologic Diseases (12) · Respiratory Hypersensitivity (12) · Respiratory Tract Diseases (12) · Rhinitis, Allergic, Perennial (12) · Rhinitis (11) · Hypersensitivity (9) · Rhinitis, Allergic (9) · Bronchial Diseases (2) · Lung Diseases (2) · Lung Diseases, Obstructive (2) · Infections (1) · Respiratory Tract Infections (1)
Antigens, Dermatophagoides (4) · CYT003-QbG10 (2) · Fish Oils (1) · Sublingual Immunotherapy (1) · dupilumab (1) · tregalizumab (1)
Cytos Biotechnology AG (2) · ASIT Biotech S.A. (1) · Circassia Limited (1) · HAL Allergy (1) · Inmunotek S.L. (1) · Johann Wolfgang Goethe University Hospital (1) · Laboratorios Leti, S.L. (1) · Miguel Blanca Gomez (1) · Stallergenes Greer (1) · T-Balance Therapeutics GmbH (1) · The University of Texas Health Science Center at San Antonio (1)
Germany (4) · Spain (2) · Argentina (1) · Canada (1) · France (1) · Poland (1) · Switzerland (1) · United States (1)
Philipp Mueller, MD (2) · Jacques Hebert, MD (1) · Jorge Fernando Maspero, MD, PhD (1) · Margitta Worm, Prof.Dr.med. (1) · Miguel Blanca, MD, PhD (1) · Pascal Demoly, MD (1) · Prof. Stefan Zielen, M.D. (1) · Stefan Zielen, Prof. Dr. (1) · Sunil K Ahuja, MD (1)
2008 (1), 2016 (1), U01AI158460 (1)